TIM3 Inhibitors Drug Clinical Trials & Market Opportunity Insight 2028 Report Highlights:
- Insight on Emerging TIM3 Inhibitors in Development As Monotherapy & combination Therapy
- Future Market Opportunity Insight From First Drug Approval: 2024 – 2028
- Insight On TIM3 Inhibitors Drug In clinical Trials: > 15 Drugs
- TIM3 Inhibitors Drug In Clinical Trials Insight By Country, Company, Indication
- Comprehensive Clinical Insight On Biomarker Identified During Clinical Trials
- TIM3 Targeted Therapy Application By Various Cancers
The advent of immune checkpoint inhibitors has greatly revolutionized the field of cancer therapeutics. However, the therapeutic success was limited to few patients due to tumor resistance, absence of tumor infiltrating lymphocytes (TIL), and presence of inhibitory myeloid cells. Moreover, the onset of immune related adverse events has been a major reason to discontinue the use of immune checkpoint inhibitors. To overcome this, researchers are continuously untangling the biology of inhibitory receptors to increase response rate and limit side-effects. Genomic analyses by researchers have led to identification of several other co-stimulatory immunoreceptors. Recently, TIM-3 has gained considerable interest among scientists owing to their critical role in cancer development and therapeutic potential for drug development. These drugs are widely used in combination with PD-1/PD-L1 or CTLA-4 immune checkpoint inhibitors and have demonstrated to overcome the drug resistance associated with them.
T-cell immunoglobulin mucin-3 (TIM-3) also known as Hepatitis A virus cellular receptor 2 (HAVCR2) has four ligands including galectin-9 (GAL-9), carcinoembryonic antigen cell adhesion molecule 1 (CEACAM-1), high-mobility group protein B1 (HMGB1), and phosphatidylserine (PS). Studies have shown that dysregulation of TIM3/Gal9 pathway results in the development of various conditions including autoimmune diseases, infections, cancers, and complications of pregnancy. In addition, high expression of TIM3 on wide range of cancer has also suggested its therapeutic potential. Current research studies are mainly focused on exploring the beneficial effects of blocking or modulating TIM-3 as therapy for cancer.
Studies have also demonstrated their promising role in combination therapy. For instance in a study, researchers treated CT26 tumor bearing mice with an anti–Tim-3 antibody, anti-PD-L1 antibody, anti–Tim-3 plus anti–PD-L1 antibodies, or control immunoglobulins. The study results demonstrated that the combined treatment with anti-TIM-3 and anti-PD-L1 resulted in dynamic reduction in tumor growth, with 50% of the mice exhibiting complete tumor regression.
At present, the robust pipeline of TIM-3 inhibitors is mainly crowded by therapeutic monoclonal antibodies. However, the advancement in the field of science and promising response of TIM-3 inhibitors in combinational therapies has led to development of several bispecific antibodies. The novel bispecific constructs helps in reducing the overall cost of development and therapy; and also enhance the efficacy of treatment. Currently, a few bispecific antibodies including AZD7789, RO7121661 and others have entered initial stages of clinical trials. Apart from cancer, researchers are also expanding the knowledge of TIM-3 inhibitors in other therapeutic indications including HIV and autoimmune disorders, which are mainly confined to preclinical stages, which will also have a positive impact on the growth of market.
Although several factors including high cost of drug development, lack of biomarkers, and government initiatives is restraining the growth of market, pharmaceutical investments in this segment is continuously increasing. The major companies in the market are GlaxoSmithKline, Novartis, Curis, Incyte Corporation, Roche, Symphogen, Sutro Biopharma, and others. The key players in the market have also strategic alliances including partnerships, acquisitions, and mergers to sustain their position in global market.
As per our report findings, the global TIM-3 inhibitor market will surpass US$ 1 Million by 2028 driven by first drug commercial launch in 2024. The rising prevalence of various cancers among the global population and rising adoption of immunotherapy to treat cancer is boosting the growth of market. The rising awareness regarding the benefits of immunotherapy over traditional therapies is further driving the demand of immunotherapy among cancer patients. The robust response of the therapy has also gained interest of several pharmaceutical giants to actively invest in this sector. Moreover, the unavailability of effectively curing cancer drugs also demands for the development of targeted therapy which will also boost the market during the forecast period.